[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","commit":"28a6975696","date":"2026-09-10","author":"Jude Gomila","message":"Tone pass: solution and mechanism first; frightening figures behind a click","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"openProblems","before":"[\"No effective screening.\", \"PARP resistance via BRCA reversion.\", \"Platinum-resistant disease remains lethal.\"]","after":"[\"No effective screening.\", \"PARP resistance via BRCA reversion.\", \"Platinum-resistant disease is the hardest setting; three drugs with survival benefit arrived in 2023-26 and each adds months, so combining and sequen..."}]},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Newly diagnosed\", approach: \"Surgery + platinum-taxane ± bevacizumab ± HIPEC; PARP maintenance by HRD status.\", refs: [\"carboplatin\", \"paclitaxel\", \"hipec\", \"olaparib\", \"niraparib\"] },\n      { sett...","after":"[\n      { setting: \"Newly diagnosed\", approach: \"Surgery + platinum-taxane ± bevacizumab ± HIPEC; PARP maintenance by HRD status.\", refs: [\"carboplatin\", \"paclitaxel\", \"hipec\", \"olaparib\", \"niraparib\"], guideline: { v..."}]}]